201000000523 end stage renal failure Diseases 0.000 description 24.208000009863 Chronic Kidney Failure Diseases 0.000 description 28.208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 102.230000000875 corresponding Effects 0.000 abstract description 4.125000003729 nucleotide group Chemical group 0.000 claims description 6.239000002773 nucleotide Substances 0.000 claims description 6.230000003276 anti-hypertensive Effects 0.000 claims description 8.206010007554 Cardiac failure Diseases 0.000 claims description 10.206010019280 Heart failure Diseases 0.000 claims description 12.208000001083 Kidney Disease Diseases 0.000 claims description 20.DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 30.208000010125 Myocardial Infarction Diseases 0.000 claims description 34.WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 44.206010012601 Diabetes mellitus Diseases 0.000 claims description 190.238000000034 method Methods 0.000 claims abstract description 50.201000010099 disease Diseases 0.000 claims abstract description 66.230000000694 effects Effects 0.000 claims abstract description 72.230000002068 genetic Effects 0.000 claims abstract description 110.230000003234 polygenic Effects 0.000 title claims abstract description 40.230000004044 response Effects 0.000 title claims abstract description 70.206010067671 Disease complication Diseases 0.000 title claims abstract description 72. 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 96.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201862685642P external-priority Application filed by Opti-Thera Inc., Les Laboratoires Servier filed Critical Opti-Thera Inc. Les Laboratoires Servier Priority date (The priority date is an assumption and is not a legal conclusion. Inventor Pavel Hamet Johanne Tremblay Original Assignee Opti-Thera Inc. Google Patents WO2019237209A1 - Polygenic risk scores for predicting disease complications and/or response to therapy WO2019237209A1 - Polygenic risk scores for predicting disease complications and/or response to therapy
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |